Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorMarco-Contelles, José
dc.contributor.authorUnzeta, Mercedes
dc.contributor.authorEsteban, Gerard
dc.contributor.authorRamsay, Rona
dc.contributor.authorRomero, Alejandro
dc.contributor.authorMartínez-Murillo, Ricardo
dc.contributor.authorCarreiras, Maria C.
dc.contributor.authorIsmaili, Lhassane
dc.contributor.authorBolea, Irene
dc.date.accessioned2016-06-28T09:30:09Z
dc.date.available2016-06-28T09:30:09Z
dc.date.issued2016-06-28
dc.identifier.citationMarco-Contelles , J , Unzeta , M , Esteban , G , Ramsay , R , Romero , A , Martínez-Murillo , R , Carreiras , M C , Ismaili , L & Bolea , I 2016 , ' ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy ' , Frontiers in Neuroscience , vol. 10 , 294 . https://doi.org/10.3389/fnins.2016.00294en
dc.identifier.issn1662-453X
dc.identifier.otherPURE: 243265429
dc.identifier.otherPURE UUID: 0d6a6aed-4e11-4942-ad84-825d8a1eb309
dc.identifier.otherScopus: 84980396145
dc.identifier.otherWOS: 000379394400001
dc.identifier.urihttp://hdl.handle.net/10023/9054
dc.descriptionMU and JMC thank MINECO (Spain) for support (Grant SAF2012-33304; SAF2015-65586-R). RRR, MU, GE and JMC thank EU (COST Action 1103) for support.en
dc.description.abstractThe complex nature of Alzheimer’s disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines showing antioxidant, anti-betaamyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ- aggregation, possessing antioxidant and neuroprotective properties.
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofFrontiers in Neuroscienceen
dc.rightsCopyright © 2016 Marco-Contelles, Unzeta, Bolea, Esteban, Ramsay, Romero, Martínez-Murillo, Carreiras and Ismaili. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.subjectMulti-target directed ligands,en
dc.subjectAlzheimer’s diseaseen
dc.subjectMonomaine oxidasesen
dc.subjectCholinesterasesen
dc.subjectDrugsen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectRA Public aspects of medicineen
dc.subject.lccRC0321en
dc.subject.lccRAen
dc.titleASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapyen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Biologyen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.identifier.doihttps://doi.org/10.3389/fnins.2016.00294
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record